Jupiter Neurosciences, Inc. Common Stock (JUNS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.32M
Last updated: Nov 17, 2026 at 11:05 AM ET
Jupiter Neurosciences, Inc. Common Stock (JUNS) Financials: Revenue, Profit and Cash Flow
Jupiter Neurosciences, Inc. Common Stock reported revenue of $21.80K for the fiscal year ended Dec 31, 2025. That year, net income was -$8.64M with a net margin of -39662.8%, operating cash flow was -$5.41M and free cash flow was -$5.41M. The quarter ended Sep 30, 2026 had revenue of $13.94K and net income of -$7.22M.
Revenue and Margins
Over the 5 years to Dec 2025, revenue fell from $1.13M, a compound annual decline of 54.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $21.80K | N/A | 80.6% | -40873.2% | -39662.8% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2022 | $233.28K | -63.4% | 100.0% | -1471.4% | -2125.2% |
| Dec 2021 | $638.04K | -43.3% | 100.0% | -612.4% | -686.4% |
| Dec 2020 | $1.13M | N/A | 100.0% | -164.4% | -146.9% |
| Dec 2019 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $21.80K | $0 | $0 | $233.28K | $638.04K | $1.13M | N/A |
| Cost of revenue | $4.23K | $0 | $0 | N/A | N/A | N/A | N/A |
| Gross profit | $17.57K | $0 | $0 | $233.28K | $638.04K | $1.13M | N/A |
| Research and development | $2.09M | $492.66K | $954.79K | $942.81K | $1.45M | $1.64M | $685.74K |
| Operating income | -$8.91M | -$3.09M | -$3.87M | -$3.43M | -$3.91M | -$1.85M | -$2.18M |
| Net income | -$8.64M | -$2.44M | -$4.78M | -$4.96M | -$4.38M | -$1.65M | -$3.05M |
| EBITDA | -$7.81M | -$2.10M | -$3.66M | N/A | N/A | -$1.64M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.94K | $24.25K | $18.65K | $21.80K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $9.61K | $21.06K | $14.29K | $17.57K | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Operating income | -$5.80M | -$2.74M | -$1.96M | -$2.81M | -$2.30M | -$2.26M | -$1.54M | -$1.47M | -$493.55K | -$557.08K | -$570.70K | -$535.64K |
| Net income | -$7.22M | -$2.27M | -$2.06M | -$2.58M | -$2.29M | -$2.25M | -$1.53M | -$1.53M | -$591.02K | $313.12K | -$634.10K | -$429.64K |
Balance Sheet
As of Dec 2025, short-term debt of $5.30M exceeded cash and equivalents by $1.51M. Shareholder equity was negative, at -$1.83M, as total liabilities of $7.40M exceeded total assets of $5.56M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $5.56M | $6.20M | $148.59K | $235.94K | $667.38K | $549.98K | $6.18K |
| Current assets | $4.82M | $4.65M | $28.74K | $69.66K | $454.67K | $549.98K | $4.97K |
| Cash and equivalents | $3.79M | $3.77M | $28.48K | $64.43K | $330.60K | $208.00K | $1.28K |
| Total liabilities | $7.40M | $2.03M | $5.95M | $7.38M | $5.85M | $4.26M | $5.02M |
| Short-term debt | $5.30M | $146.43K | $2.02M | $1.78M | $486.80K | $108.48K | $1.21M |
| Long-term debt | N/A | N/A | $106.71K | N/A | N/A | N/A | N/A |
| Shareholder equity | -$1.83M | $4.17M | -$5.80M | -$7.14M | -$5.18M | -$3.71M | -$5.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.62M | $3.72M | $3.95M | $5.56M | $2.58M | $3.97M | $4.96M | $6.20M | $85.55K | $136.75K | $116.82K | $148.59K |
| Total liabilities | $2.79M | $4.08M | $6.73M | $7.40M | $2.52M | $2.63M | $1.90M | $2.03M | $5.84M | $5.49M | $6.14M | $5.95M |
| Cash and equivalents | $300.62K | $1.52M | $2.36M | $3.79M | $723.80K | $1.88M | $2.71M | $3.77M | $253 | $14.85K | $8.31K | $28.48K |
| Shareholder equity | -$1.16M | -$365.97K | -$2.78M | -$1.83M | $57.42K | $1.34M | $3.06M | $4.17M | -$5.75M | -$5.36M | -$6.02M | -$5.80M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.41M | -$3.91M | -$480.95K | -$1.25M | -$1.74M | -$254.78K | -$142.95K |
| Capital expenditures | $4 | $4 | $3 | $4 | $4 | $0 | $0 |
| Free cash flow | -$5.41M | -$3.91M | -$480.96K | -$1.25M | -$1.74M | -$254.78K | -$142.95K |
| Financing cash flow | $5.43M | $7.65M | $445.00K | $982.33K | $1.86M | $461.50K | $107.79K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.72M | -$2.29M | -$1.43M | -$2.37M | -$1.15M | -$828.22K | -$1.06M | -$3.70M | -$42.60K | -$107.46K | -$65.17K | -$161.14K |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5 | $0 |
| Free cash flow | N/A | N/A | -$1.43M | -$2.37M | -$1.15M | -$828.22K | -$1.06M | -$3.70M | -$42.60K | -$107.46K | -$65.17K | -$161.14K |
Frequently Asked Questions About JUNS
What is Jupiter Neurosciences, Inc. Common Stock's annual revenue?
Jupiter Neurosciences, Inc. Common Stock reported revenue of $21.80K for the fiscal year ended Dec 31, 2025.
Is Jupiter Neurosciences, Inc. Common Stock profitable?
No. Jupiter Neurosciences, Inc. Common Stock reported net income of -$8.64M for the fiscal year ended Dec 31, 2025, with a net margin of -39662.8%.
How much free cash flow does JUNS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.41M minus capital expenditures of $4 produced free cash flow of -$5.41M.
How much debt does Jupiter Neurosciences, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $5.30M and cash and equivalents of $3.79M.
What is JUNS's profit margin?
For the fiscal year ended Dec 31, 2025, Jupiter Neurosciences, Inc. Common Stock reported gross margin of 80.6%, operating margin of -40873.2% and net margin of -39662.8%.
JUNS pages: Overview, Financials, Competitors